COHANCE · NSE
Cohance Lifesciences Limited
₹462.3
+0.62% (+₹2.85)
Prev. close
₹459.45
Volume
3,18,955
Delivery %
46.2%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Cohance Lifesciences, projecting a 17% upside with a target price of ₹1,150. The brokerage highlights strong …” | Jefferies AnalysisJefferies | Cohance Lifesciences | MISS | |
| “Initiated with a 'Buy' rating on Cohance Lifesciences, setting a target price of Rs 1,150, implying a 28% upside from it…” | Jefferies AnalysisJefferies | Cohance Lifesciences | MISS | |
| “Initiates coverage on Suven Pharmaceuticals with a 'Buy' rating and a target price of Rs 1,400, implying an upside of ~1…” | ICICI Securities AnalysisICICI Securities | Cohance Lifesciences Limited | MISS | |
| “Bullish on Suven Pharmaceuticals, recommending a buy at ₹1224 with a target of ₹1308 and a stop loss at ₹1179, based on …” | Sumeet BagadiaChoice Equity Broking | Cohance Lifesciences Limited | PENDING |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Cohance Lifesciences is a potential entrant from the small-cap to mid-cap category in AMFI's January 2026 review, effect…” | Abhilash PagariaNuvama | Cohance Lifesciences | — |
Fundamentals
About Cohance Lifesciences Limited
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms (FDE); packaging and clinical trial support services; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Umang Vohra B.E., M.B.A.
Headquarters
Hyderabad
Website
cohance.comExchange
View on NSE ↗Key stats
Market cap
₹17,234.10 Cr
P/E ratio (TTM)
165.0
Dividend yield
0.00%
EPS (TTM)
₹2.73
Beta (1Y · daily vs NIFTY 50)
0.84
Beta (5Y · monthly vs NIFTY 50)
1.15
Shares float
13.81 Cr
EPS · quarter ended Jun 2026
₹-0.65
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
Left off as not meaningful (growth from a very small base, beyond ±400%): Trade receivables FY25 (+478%).
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,009.72 Cr | ₹1,320.22 Cr | ₹1,340.33 Cr | ₹1,034.06 Cr | ₹2,526.22 Cr | ₹2,268.55 Cr | |
EBITDA | ₹454.72 Cr | ₹671.81 Cr | ₹620.53 Cr | ₹467.22 Cr | ₹847.42 Cr | ₹431.61 Cr |
| ₹362.00 Cr | ₹453.80 Cr | ₹411.29 Cr | ₹300.28 Cr | ₹487.34 Cr | ₹179.23 Cr | |
Diluted EPS | ₹14.23 | ₹17.83 | ₹16.16 | ₹11.8 | ₹12.68 | ₹4.68 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,474.00 Cr | ₹1,830.00 Cr | ₹1,966.00 Cr | ₹2,254.00 Cr | ₹5,480.00 Cr | ₹5,727.00 Cr | |
| ₹143.04 Cr | ₹97.13 Cr | ₹70.34 Cr | ₹65.01 Cr | ₹485.93 Cr | ₹400.49 Cr | |
Stockholders' equity | ₹1,180.00 Cr | ₹1,527.00 Cr | ₹1,735.00 Cr | ₹2,050.00 Cr | ₹3,648.00 Cr | ₹3,911.00 Cr |
CWIP, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹383.00 Cr | ₹330.00 Cr | ₹457.00 Cr | ₹358.00 Cr | ₹673.00 Cr | ₹368.00 Cr | |
Investing cash flow | ₹-311.40 Cr | ₹-136.14 Cr | ₹-194.84 Cr | ₹-362.35 Cr | ₹-389.70 Cr | ₹-254.57 Cr |
| ₹-76.00 Cr | ₹-156.00 Cr | ₹-242.00 Cr | ₹-14.00 Cr | ₹-327.00 Cr | ₹-165.00 Cr | |
Capital expenditure | ₹-111.00 Cr | ₹-75.00 Cr | ₹-286.00 Cr | ₹-52.00 Cr | ₹-317.00 Cr | ₹-220.00 Cr |
End cash position | ₹7.18 Cr | ₹44.56 Cr | ₹64.80 Cr | ₹47.23 Cr | ₹96.65 Cr | ₹49.14 Cr |
Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 23(10Q) | Mar 24–Mar 25(5Q) | May 25–Jun 25(2Q) | Sep 25–Jun 26(4Q) |
|---|---|---|---|---|
| Promoter | 60.00% | 50.10% | 66.41% | 57.49% |
| Public | 40.00% | 49.90% | 33.59% | 42.51% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Cohance Lifesciences Limited | ₹17,086.80 Cr | ₹440.35 | 163.6 | 4.37 | 4.6% | 0.10 | -12.8% | -40.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.